Corrigendum to "Tanshinone IIA reduces lethality and acute lung injury in LPS-treated mice by inhibition of PLA2 activity" [European Journal of Pharmacology 607 (2009) 194-200] (DOI:10.1016/j.ejphar.2009.02.003);Tanshinone IIA reduces lethality and acute lung injury in LPS-treated mice by inhibition of PLA2 activity

European Journal of Pharmacology

Volumn 607, Issue 1-3, 2009, Pages 194-200

  Xu, Min ^a,b   Dong, Ming Qing ^a   Cao, Fa Le ^c   Liu, Man Ling ^a   Wang, Yan Xia ^a   Dong, Hai Ying ^a   Huang, Yu Fang ^a   Liu, Yi ^a   Wang, Xiao Bin ^a   Zhang, Bo ^a   Zhao, Peng Tao ^a   Luo, Ying ^a   Niu, Wen ^a   Cui, Yan ^a   Li, Zhi Chao ^a,b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Acute lung injury; Lethality; Lipopolysaccharide; PLA2; Tanshinone IIA

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUKOTRIENE B4; LIPOPOLYSACCHARIDE; MYELOPEROXIDASE; PHOSPHOLIPASE A2; PROSTAGLANDIN E2; PROTEIN; TANSHINONE IIA; THROMBOXANE B2;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; LETHALITY; LUNG ALVEOLUS EPITHELIUM; LUNG HOMOGENATE; LUNG LAVAGE; METABOLITE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; WESTERN BLOTTING;

EID: 62149088918     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.03.043     Document Type: Erratum

References (40)

1. aoui-El-Azher M., Wu Y., Havet N., Israel A., Lilienbaum A., and Touqui L. Arachidonic acid differentially affects basal and lipopolysaccharide-induced sPLA(2)-IIA expression in alveolar macrophages through NF-kappaB and PPAR-gamma-dependent pathways. Mol. Pharmacol. 61 (2002) 786-794
2. Attalah H.L., Wu Y., aoui-El-Azher M., Thouron F., Koumanov K., Wolf C., Brochard L., Harf A., Delclaux C., and Touqui L. Induction of type-IIA secretory phospholipase A2 in animal models of acute lung injury. Eur. Respir. J. 21 (2003) 1040-1045
3. Cavaillon J.M., Fitting C., Haeffner-Cavaillon N., Kirsch S.J., and Warren H.S. Cytokine response by monocytes and macrophages to free and lipoprotein-bound lipopolysaccharide. Infect. Immunol. 58 (1990) 2375-2382
4. Chen S.F., and Wu Z.L. The convenient and quick mensuration of phospholipase A2 in body fluid and tissue. Acad. J. Sec. Mil. Med. Univ. 10 (1989) 254-256
5. Chen T.H., Hsu Y.T., Chen C.H., Kao S.H., and Lee H.M. Tanshinone IIA from Salvia miltiorrhiza induces heme oxygenase-1 expression and inhibits lipopolysaccharide-induced nitric oxide expression in RAW 264.7 cells. Mitochondrion 7 (2007) 101-105
6. Choi H.S., Cho D.I., Choi H.K., Im S.Y., Ryu S.Y., and Kim K.M. Molecular mechanisms of inhibitory activities of tanshinones on lipopolysaccharide-induced nitric oxide generation in RAW 264.7 cells. Arch. Pharm. Res. 27 (2004) 1233-1237
7. Deryckere F., and Gannon F. A one-hour minipreparation technique for extraction of DNA-binding proteins from animal tissues. Biotechniques 16 (1994) 405
8. Du G., and Zhang J. The general situation and progress of the modern research of red sage root (Radix Salviae miltiorrhizae). Zhong Yao Cai 28 (2004) 301-304
9. Fenton M.J., and Golenbock D.T. LPS-binding proteins and receptors. J. Leukoc. Biol. 64 (1998) 25-32
10. Figueroa D.J., Breyer R.M., Defoe S.K., Kargman S., Daugherty B.L., Waldburger K., Liu Q., Clements M., Zeng Z., O'Neill G.P., Jones T.R., Lynch K.R., Austin C.P., and Evans J.F. Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am. J. Respir. Crit. Care Med. 163 (2001) 226-233
11. Filler G., Priem F., Vollmer I., Gellermann J., and Jung K. Diagnostic sensitivity of serum cystatin for impaired glomerular filtration rate. Pediatr. Nephrol. 13 (1999) 501-505
12. Fowler A.A., Hamman R.F., Good J.T., Benson K.N., Baird M., Eberle D.J., Petty T.L., and Hyers T.M. Adult respiratory distress syndrome: risk with common predispositions. Ann. Intern. Med. 98 (1983) 593-597
13. Furue S., Kuwabara K., Mikawa K., Nishina K., Shiga M., Maekawa N., Ueno M., Chikazawa Y., Ono T., Hori Y., Matsukawa A., Yoshinaga M., and Obara H. Crucial role of group IIA phospholipase A(2) in oleic acid-induced acute lung injury in rabbits. Am. J. Respir. Crit. Care Med. 160 (1999) 1292-1302
14. Furue S., Mikawa K., Nishina K., Shiga M., Ueno M., Tomita Y., Kuwabara K., Teshirogi I., Ono T., Hori Y., Matsukawa A., Yoshinaga M., and Obara H. Therapeutic time-window of a group IIA phospholipase A2 inhibitor in rabbit acute lung injury: correlation with lung surfactant protection. Crit. Care Med. 29 (2001) 719-727
15. Glauser M.P., Zanetti G., Baumgartner J.D., and Cohen J. Septic shock: pathogenesis. Lancet 338 (1991) 732-736
16. Hino M., Kohchi C., Nishizawa T., Yoshida A., Nakata K., Inagawa H., Hori H., Makino K., Terada H., and Soma G. Innate-immune therapy for lung carcinoma based on tissue-macrophage activation with lipopolysaccharide. Anticancer Res. 25 (2005) 3747-3754
17. Hudson L.D., Milberg J.A., Anardi D., and Maunder R.J. Clinical risks for development of the acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 151 (1995) 293-301
18. Ishii S., and Shimizu T. Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Prog. Lipid Res. 39 (2000) 41-82
19. Ishii S., Nagase T., Tashiro F., Ikuta K., Sato S., Waga I., Kume K., Miyazaki J., and Shimizu T. Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor. EMBO J. 16 (1997) 133-142
20. Ishii S., Kuwaki T., Nagase T., Maki K., Tashiro F., Sunaga S., Cao W.H., Kume K., Fukuchi Y., Ikuta K., Miyazaki J., Kumada M., and Shimizu T. Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. J. Exp. Med. 187 (1998) 1779-1788
21. Jang S.I., Jeong S.I., Kim K.J., Kim H.J., Yu H.H., Park R., Kim H.M., and You Y.O. Tanshinone IIA from Salvia miltiorrhiza inhibits inducible nitric oxide synthase expression and production of TNF-alpha, IL-1beta and IL-6 in activated RAW 264.7 cells. Planta Med. 69 (2003) 1057-1059
22. Jang S.I., Kim H.J., Kim Y.J., Jeong S.I., and You Y.O. Tanshinone IIA inhibits LPS-induced NF-kappaB activation in RAW 264.7 cells: possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways. Eur. J. Pharmacol. 542 (2006) 1-7
23. Jones B.G., Dickinson P.A., Gumbleton M., and Kellaway I.W. Lung surfactant phospholipids inhibit the uptake of respirable microspheres by the alveolar macrophage NR8383. J. Pharm. Pharmacol. 54 (2002) 1065-1072
24. Kabir K., Gelinas J.P., Chen M., Chen D., Zhang D., Luo X., Yang J.H., Carter D., and Rabinovici R. Characterization of a murine model of endotoxin-induced acute lung injury. Shock 17 (2002) 300-303
25. Kang B.Y., Chung S.W., Kim S.H., Ryu S.Y., and Kim T.S. Inhibition of interleukin-12 and interferon-gamma production in immune cells by tanshinones from Salvia miltiorrhiza. Immunopharmacology 49 (2000) 355-361
26. Kim J.K. Illustrated Natural Drugs Encyclopedia (1989), Namsandan Publishers, Seoul 160
27. Koike K., Yamamoto Y., Hori Y., and Ono T. Group IIA phospholipase A2 mediates lung injury in intestinal ischemia-reperfusion. Ann. Surg. 232 (2000) 90-97
28. Kollef M.H., and Schuster D.P. The acute respiratory distress syndrome. N. Engl. J. Med. 332 (1995) 27-37
29. Li P.F., Dietz R., and von H.R. Differential effect of hydrogen peroxide and superoxide anion on apoptosis and proliferation of vascular smooth muscle cells. Circulation 96 (1997) 3602-3609
30. Lin R., Wang W.R., Liu J.T., Yang G.D., and Han C.J. Protective effect of tanshinone IIA on human umbilical vein endothelial cell injured by hydrogen peroxide and its mechanism. J. Ethnopharmacol. 108 (2006) 217-222
31. Liu Z., Gao S., Deng J., and Li H. The effect of cardiotonic pill on coronary heart disease with symptom of angina. J. Chin. Patent Med. 19 (1997) 20-21
32. Nagase T., Ishii S., Kume K., Uozumi N., Izumi T., Ouchi Y., and Shimizu T. Platelet-activating factor mediates acid-induced lung injury in genetically engineered mice. J. Clin. Invest. 104 (1999) 1071-1076
33. Nagase T., Uozumi N., Ishii S., Kume K., Izumi T., Ouchi Y., and Shimizu T. Acute lung injury by sepsis and acid aspiration: a key role for cytosolic phospholipase A2. Nat. Immunol. 1 (2000) 42-46
34. Nagase T., Uozumi N., oki-Nagase T., Terawaki K., Ishii S., Tomita T., Yamamoto H., Hashizume K., Ouchi Y., and Shimizu T. A potent inhibitor of cytosolic phospholipase A2, arachidonyl trifluoromethyl ketone, attenuates LPS-induced lung injury in mice. Am. J. Physiol., Lung Cell. Mol. Physiol. 284 (2003) L720-L726
35. Pittet J.F., Mackersie R.C., Martin T.R., and Matthay M.A. Biological markers of acute lung injury: prognostic and pathogenetic significance. Am. J. Respir. Crit. Care Med. 155 (1997) 1187-1205
36. Prescott S.M., McIntyre T.M., and Zimmerman G. Two of the usual suspects, platelet-activating factor and its receptor, implicated in acute lung injury. J. Clin. Invest. 104 (1999) 1019-1020
37. Schaloske R.H., and Dennis E.A. The phospholipase A2 superfamily and its group numbering system. Biochim. Biophys. Acta 1761 (2006) 1246-1259
38. Shi X.M., Huang L., Xiong S.D., and Zhong X.Y. Protective effect of tanshinone II A on lipopolysaccharide-induced lung injury in rats. Chin. J. Integr. Med. 13 (2007) 137-140
39. Touqui L., and Arbibe L. A role for phospholipase A2 in ARDS pathogenesis. Mol. Med. Today 5 (1999) 244-249
40. Zhu G.F., Sun B., Niu S.F., Cai Y.Y., Lin K., Lindwall R., and Robertson B. Combined surfactant therapy and inhaled nitric oxide in rabbits with oleic acid-induced acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 158 (1998) 437-443